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This study sought to evaluate serology and PCR as tools for measuring BK virus (BKV) replication. Levels
of immunoglobulin G (IgG), IgM, and IgA against BKV capsids were measured at five time points for 535 serial
samples from 107 patients by using a virus-like particle-based enzyme-linked immunosorbent assay. Viral DNA
in urine and plasma samples was quantitated. The seroconversion rate was 87.5% (14/16); 78.6% (11/14) and
14.3% (2/14) of patients who seroconverted developed viruria and viremia, respectively. Transient serorever-
sion was observed in 18.7% of patients at 17.4  11.9 weeks posttransplant and was not attributable to loss of
antigenic stimulation, changes in immunosuppression, or antiviral treatment. Titers for anti-BK IgG, IgA, and
IgM were higher in patients with BKV replication than in those without BKV replication. A rise in the optical
density (OD) of anti-BK IgA (0.19), IgM (0.04), or IgG (0.38) had a sensitivity of 76.6 to 88.0% and a specificity
of 71.7 to 76.1% for detection of viruria. An anti-BK IgG- and IgA-positive phenotype at week 1 was less
frequent in patients who subsequently developed viremia (14.3%) than in those who subsequently developed
viruria (42.2%) (P 0.04). Anti-BK IgG OD at week 1 showed a weak negative correlation with peak urine viral
load (r  0.25; P  0.05). In summary, serial measurements of anti-BKV immunoglobulin class (i) detect
onset of viral replication, (ii) document episodes of seroreversion, and (iii) can potentially provide prognostic
information.
BK virus (BKV) belongs to the genus Polyomaviridae and is
now a well-recognized pathogen in kidney transplant recipi-
ents. Its virions are 45 nm in diameter and have a 5-kb double-
stranded, circular, supercoiled DNA, which is encased in a
protein capsid (11). Primary infection is believed to occur early
in life via the respiratory route. This is followed by viral latency
in the urogenital tract. BKV reactivation with urinary excretion
of virus occurs in 10 to 60% of kidney transplant recipients.
Viremia develops in 5 to 25% patients, and approximately 1 to
10% have biopsy-documented viral nephropathy (BKVN) (14–
16, 27, 34, 35, 39–41, 43, 45, 51). BKVN has also been de-
scribed to occur in the native kidneys of liver, heart, and bone
marrow transplant recipients and in patients with congenital
immunodeficiency or AIDS (10, 44, 45, 51). Diagnosis of
BKVN is primarily based on histological examination, al-
though persistent viremia has been used as a surrogate marker
for this complication (36). Initial clinical series of BKVN were
characterized by a graft loss that exceeded 50%. In recent
years, intensive monitoring techniques have been used to fa-
cilitate early diagnosis and prevent irreversible graft injury
leading to graft loss.
Much remains to be learned about the humoral immune
response to polyomavirus infection in humans. Classic publi-
cations were based primarily on hemagglutination inhibition
assays (12, 13, 17, 18, 19, 28, 31, 37, 47). Immunoglobulin
classes were usually not measured, and the patients studied
were not well characterized from a clinical perspective. Several
recent studies have used enzyme-linked immunosorbent assay
(ELISA) technology and have shown marked elevations in
anti-BKV antibodies in patients with active viral replication (4,
22, 23, 31, 42). It has been difficult to show definitively whether
this intense humoral immune response actually contributes to
resolution of viral nephropathy. Available data suggest that
early infection can be frequently derived from the donor kid-
ney (4, 5). The use of serial antibody testing as a tool to screen
for BKV infection remains to be evaluated formally. There are
also few data on the clinical utility of measuring immunoglob-
ulin isotypes with respect to diagnosis and prognosis. To ad-
dress these issues, we have measured levels of immunoglobulin
G (IgG), IgA, and IgM antibodies against BKV virus-like par-
ticles (VLPs) in a well-characterized set of 535 samples derived
from 107 kidney transplant recipients.
MATERIALS AND METHODS
This study is based on preexisting, deidentified human specimens and associ-
ated clinical data obtained from the Washington University Kidney Translational
Research Core (KTRC). Institutional Review Board approval was obtained at
Washington University under the original protocol “A Randomized Prospective
Controlled Clinical and Pharmacoeconomic Study of Cyclosporine versus
Tacrolimus in Adult Renal Transplant Recipients,” Washington University
School of Medicine, Human Studies Committee no. 00-0951, with continuation
under the title “Polyomavirus and Mentoring in Renal Transplantation.” De-
tailed clinical features and immunosuppression protocols for these patients have
previously been published (1, 5, 6). Briefly, these patients were enrolled in a
prospective open-label trial and randomized to receive tacrolimus or cyclospo-
* Corresponding author. Mailing address: Department of Pathol-
ogy, Division of Transplant Pathology, University of Pittsburgh, E737
UPMC-Montefiore Hospital, 3459 Fifth Ave., Pittsburgh, PA 15213.
Phone: (412) 647-7646. Fax: (412) 647-5237. E-mail: randhawapa
@msx.upmc.edu.
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rine in a 2:1 block design. Exclusion criteria included patients who were preg-
nant, nursing, or seropositive for other viral infections (human immunodefi-
ciency virus, human T-cell leukemia virus type 1, or hepatitis virus). Patients with
histories of rabbit anti-T-cell polyclonal agents were also not included. The age
ranges were 44  13 years for tacrolimus-treated patients and 46  13 years for
cyclosporine-treated patients. Males constituted 64% and 61% of these two
treatment arms, respectively. Overall, 64 patients in this study developed viruria
on at least one occasion, of which 14 also became viremic. As defined by positive
test results for viral DNA with two consecutive samples, 48 patients had persis-
tent viruria, while only 2 had persistent viremia. At the 1-year follow-up, 40
patients remained viruric, but none was viremic.
Recipients were prospectively monitored for BK viruria, viremia, and ne-
phropathy. Identification of viremia triggered discontinuation of the antimetab-
olite component of the immunosuppressive regimen. This maneuver successfully
prevented the development of nephropathy in this cohort, although no protocol
biopsies were performed to rule out subclinical nephropathy.
A total of 535 serial plasma and urine samples were retrieved from 107
patients, of whom 50 had viruria, 14 had both viruria and viremia, and 43 were
negative for BKV DNA by PCR. No patient had viremia in the absence of
viruria. These were all essentially “samples of convenience” that had previously
been collected at 1, 4, and 12 weeks; 6 months; and 1 year posttransplant with the
aforementioned protocol. BKV DNA was measured by a published quantitative
PCR assay that targets the large T-antigen gene and has a lower limit of sensi-
tivity equivalent to 4,000 viral copies per ml (1). BK viruria and viremia were
defined as the presence of viral DNA as determined by PCR in urine and plasma
samples, respectively. Detection of viral DNA in either fluid was regarded as
evidence of viral replication.
For this study, BKV-specific antibodies in plasma samples were measured
using a VLP-based ELISA (42). This assay does not show cross-reactivity with
anti-JC virus antibodies. Briefly, the ELISA protocol consisted of coating micro-
titer plates with purified VLP protein (0.2 g/well), followed by treatment with
a blocking solution. Diluted serum samples (1:100 for IgA and IgM and 1:200 for
IgG), in duplicate, were allowed to react on the antigen-coated plates, and
antigen-bound immunoglobulin was detected with peroxidase-conjugated anti-
bodies to human IgG, IgA, or IgM (Southern BioTech, Birmingham, AL). IgA
and IgM measurements were performed after an initial blocking step with 15%
goat anti-human IgG (Sigma-Aldrich, St. Louis, MO). Color development was
initiated by addition of substrate, and optical density (OD) was measured at 405
nm with an automated microtiter plate reader. Positive and negative control sera,
sensitivity controls, and reproducibility controls were included in each run. Runs
where replicate serum values fell outside the expected coefficient of variation
(7.9%) were repeated. Results are recorded both as OD values and as categorical
variables (seropositive or seronegative) based on cutoff points determined by
assaying known seronegative subjects.
The OD cutoff points used to distinguish seronegative and seropositive sub-
jects for the VLP batch used in this study were 0.075, 0.150, and 0.080 for anti-BK
IgG, IgA, and IgM antibodies, respectively. For every patient, change in anti-BK
IgG ( anti-BK IgG), IgA, or IgM was defined as the difference between the
peak OD and the baseline OD ( OD) for the immunoglobulin class of interest.
Patients who were seronegative for BKV at week 1 and subsequently became
seropositive were considered to represent primary infection, although we could
not definitively rule out a prior exposure with subsequent seroreversion or an
antibody level below the detection limit of the assay. Reactivation infection was
defined as the appearance of anti-BK IgA or IgM antibodies in patients who had
only an anti-BK IgG antibody detected at week 1. Patients who had anti-BK IgA
or IgM detectable at week 1 could not be definitively categorized as having either
primary or reactivation infection, since time zero samples were not analyzed.
However, given the high seroprevalence for BKV in healthy donors, it is likely
that the majority of these were reactivation infections.
For statistical analysis, basic demographics were described using measures of
central tendency (means and medians) and spread (standard deviation and range)
for continuous data and frequencies and percentages for categorical data. Compar-
isons between groups were performed using rank sum and exact chi-square tests.
Correlations between viral load and serologic parameters were obtained using
Spearman correlation coefficients. To identify potential cutoff values for immuno-
globulin isotopes and BKV infection, sensitivity, specificity, positive predictive value,
and negative predictive value were obtained. Power calculations were not per-
formed, as there are no prospectively collected data available on the prevalences of
anti-BK IgA, IgM, and IgG antibodies. All statistical analyses were performed using
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An overview of the serial serologic and viral load studies
performed on these patients is presented in Table 1, and a
discussion of the salient features follows.
Seroprevalence. The majority of subjects studied had evi-
dence of past exposure to BKV, as judged by the presence of
anti-BK IgG antibodies 1 week after transplantation. The pro-
portions of seronegative subjects varied between 11.6 and
17.2% in different categories of patients (Table 2). Anti-BKV
IgA antibodies together with anti-BK IgG were found in week
1 samples obtained from 42.2% of patients with BK viruria
and, interestingly, in almost the same proportion (44.2%) of
patients who were BKV PCR negative. A significantly lower
proportion (14.3%) of IgA- and IgG-positive (IgA IgG)
patients at week 1 subsequently became viremic patients (P 
0.04). Anti-BKV IgM antibodies were never found without
anti-IgA or -IgG in any clinical category. However, the com-
bination of IgM, IgA, and IgG antibodies was found in 16.3%
of PCR-negative, 7.8% of viruric, and 14.3% of viremic sub-
jects.
Primary seroconversion. Sixteen subjects were BKV sero-
negative at week 1, of whom 14 seroconverted by 1 year
(14/16; 87.5%) (Table 3). In the first sample showing sero-
conversion, anti-BK IgG alone was detected in five patients
and IgA alone in one patient, and combinations of more
than one immunoglobulin were detected in eight patients
(three IgG-IgA, two IgG-IgM, and three IgG-IgA-IgM).
These 14 primary infections were characterized by absence
of viruria (3/14; 21.4%), presence of viruria (11/14; 78.6%;
two at time points other than those shown in Table 3), or
presence of viremia (2/14; 14.3%; both patients were also
viruric).
Seroreversion. Of the 91 subjects demonstrated to be BKV
seropositive at 1 week posttransplant, 17 (18.7%) showed tran-
sient loss of all antibodies during the follow-up period (Table
4). Typically, this occurred at 4 weeks to 6 months posttrans-
plant (mean, 17.4  11.9 weeks). Anti-BK IgG antibodies were
lost in all patients, anti-BK IgA antibodies in all but two pa-
tients (no. 2 and 4), and anti-BK IgM antibodies in three
patients (no. 8, 14, and 17). At the time that seroreversion was
detected, 8/17 (47%) patients (no. 3, 4, 11, 12, 13, 15, 16, and
17) were found to be viruric. Four (24%) patients had docu-
mented viruria prior to diagnosis of seroreversion and contin-
ued to excrete virus in urine afterwards (no. 4, 11, 12, and 14).
TABLE 2. Baseline serostatus and immunoglobulin optical density in patients classified by virologic outcome
Serostatus or
antibody
No. (%) of patients with: OD for patients with:
No BKV BK viruria BK viremia No BKV BK viruria BK viremia
Seronegative 5 (11.6) 11 (17.2) 2 (14.3)
IgG only 12 (27.9) 19 (29.6) 8 (57.1)
IgG IgM 0 2 (3.1) 0
IgG IgA 19 (44.2) 27 (42.2) 2 (14.3)a
IgG IgM IgA 7 (16.3) 5 (7.8) 2 (14.3)
IgG 0.75  0.55 0.77  0.6 0.68  0.57
IgM 0.05  0.03 0.06  0.07 0.05  0.05
IgA 0.25  0.21 0.22  0.21 0.15  0.19b
a P was 0.04 for comparison with nonviremic patients.
b P was 0.08 for comparison with nonviremic patients.
TABLE 3. BKV seroconversion in kidney transplant recipientsa
Patient
Serostatus (viral loadb of urinary sample)
1 wk 4 wks 12 wks 6 mos 12 mos
1  G G G G
2     
3     
4   GAM GAM GAM
5  A AM G 
6  G GA  G
7  G G G G
8  (0)  (0.00) GM (7.97) GAM (0) GAM (0)
9  (0)  (5.42)  (7.10) GA (NA) GAM (5.09)
10  (0) G (0)  (6.52) GAM (7.88) GAM (8.71)
11  (0)  (0)  (6.98) GAM (UTQ) GAM (0)
12  (0) GA (0) GA (7.51)  (NA) GAM (UTQ)
13  (0)  (0) GAM (0) GAM (0) GAM (5.49)
14  (0) GM (5.07) G (5.90) GAM (5.64)  (UTQ)
15  (0) GA (11.01) GAM (UTQ) GAM (0) GAM (6.61)
16  (0) G (0) G (8.87) GAM (6.20) GAM (UTQ)
a The immunoglobulin isotype(s) detected at each time point is designated  (seronegative), G, A, or M. UTQ, unable to quantitate (these samples contained viral
DNA below the linear range of the real-time PCR assay 4,000 copies/ml); NA, not available.
b For patients who developed viruria, urinary viral load in log numbers of copies/ml is indicated.
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One patient (no. 10) became viruric for the first time after
seroreversion. Seven of seventeen patients (41.0%) did not
develop viruria or viremia at any time during the 1-year period
of observation (no. 1, 2, and 5 to 9).
Reactivation infections. Patients with only anti-BK IgG an-
tibodies detected at week 1 were interpreted as having been
exposed to BKV infection prior to transplantation (n  31).
The subsequent appearance of anti-BK IgA and anti-BK IgM
antibodies was used to indicate a posttransplant reactivation
infection. Patients with anti-BK IgA or IgM detectable in the
week 1 sample itself were not classified as having reactivation
infection, since, in the absence of a day zero sample, the less
likely possibility of a primary infection could not be ruled out.
In 22/31 (70.9%) patients who could be categorized as having
reactivation infection, IgA was detected first in 13 patients and
IgM first in 1 patient. In eight patients, IgA and IgM appeared
to develop simultaneously, according to the sampling time
points chosen for this study (data not shown). Viruria devel-
oped in 16/22 (72.7%) and viremia in 7/22 (31.8%) patients,
and these proportions are similar to those observed in patients
undergoing primary seroconversion (see above).
Diagnostic value of antibody isotypes. Immunoglobulin ti-
ters as measured by OD were higher for all three classes in
samples taken at the time of positive PCR from urine or
plasma than in samples taken when PCR showed no evidence
of BKV replication (anti-BK IgG, 1.43  0.74 versus 0.88 
0.64; anti-BK IgA, 0.59  0.46 versus 0.30  0.32; anti-BK
IgM, 0.19  0.19 versus 0.08  0.09) (Table 5). OD cutoff
values of 1.8, 0.84, and 0.24 for IgG, IgA, and IgM, respec-
tively, could predict urine PCR-positive and PCR-negative
time points with 32.6 to 95.1% specificity and 28.6 to 41.7%
sensitivity (Table 6). The positive predictive values and nega-
tive predictive values were in the range of 64.6 to 71.7% and
76.0 to 78.5%, respectively. Sensitivity of detection was signif-
icantly improved by taking into account temporal changes in
antibody titer.  anti-BK IgG,  anti-BK IgA, and  anti-BK
IgM cutoff values of 0.38, 0.19, and 0.04, respectively, were
associated with diagnostic sensitivities of 85.9, 88.0, and 76.6%,
respectively (Table 6). The negative predictive values were also
improved by 10 to 20%, but the positive predictive values were
not affected. While the higher ODs in viremic patients could, in
part, be due to reduction in immunosuppression, this cannot
be said about the viruric patients, in whom a positive PCR test
result did not trigger any therapeutic manipulation.
Temporal relationships between humoral immune response
and onset of viral replication. In patients with primary infec-
tion (Table 3), a positive PCR result preceded detection of
anti-BK IgA or anti-BK IgM antibodies in four of nine (44.4%)
patients who became viruric (no. 9, 10, 11, and 16). Serocon-
version and positive PCR results were noted at the same time
point in three of nine (33.3%) patients (no. 8, 14, and 15)
(Table 1). In two of nine (22.2%) patients (no. 12 and 13),
anti-BK IgA or anti-BK IgM detection occurred prior to a
detectable viruria. A similar temporal relationship was ob-
served in the setting of reactivation infection (data not shown).
However, as previously noted, anti-BK IgA antibodies were
frequently present at week 1 even in patients who never went
on to develop BK viruria. These patients were not classified as
having either primary or reactivation infection but were re-
garded as indeterminate for infection status. When temporal
relationships in all patients taken together were considered,
the mean time to anti-BK IgA detection (6.9 11.4 weeks) was
found to be less than the time to detection of viral DNA (14.6 
14.9 weeks) or anti-BK IgM antibodies (16.8  16.7 weeks).
Relationships between antibody titers and viral load. Base-
line anti-BK IgA OD at week 1 (Table 2) tended to be lower in
patients who went on to develop viremia (0.15  0.19) than in
those who developed viruria (0.22 0.21) or no viruria (0.25
0.21) (P values of 0.08 for viremic versus nonviremic patients).
Viremic subjects also had a lower baseline seroprevalence of
anti-BK IgA (P  0.04) (Table 2). Baseline anti-BK IgG OD
showed a weak inverse correlation with peak urine viral load
(r  0.25; P  0.05) (Fig. 1, upper). Direct correlations were
observed between urine viral load and  OD for all three
TABLE 4. BKV seroreversion in kidney transplant recipientsa
Patient
Serostatus (viral loadb of urinary sample)
1 wk 4 wks 12 wks 6 mos 12 mos
1 G GA G  G
2 G G G  
3 G (0) GA (0)  (UTQ) GA (9.01) GA (5.92)
4 G (5.74)  (11.32) GAM (7.48) GAM (5.1) GAM (5.42)
5 GA G GA  G
6 GA GA G  G
7 GA  GA GA GA
8 GA G GAM  
9 GA GA GA  GA
10 GA (0)  (0) GA (6) GA (0) GA (0)
11 NA (NA) GA (0) GA (6.98)  (7.54) GAM (UTQ)
12 GA (5.53) GA (8.53)  (6.65) GA (6.99) GAM (0)
13 GA (0) GA (0)  (5.05) NA (NA) NA (NA)
14 GA (UTQ) GA (8.94) GA (9.54) GAM (5.87)  (UTQ)
15 GA (0) GA (0) GA (0)  (7.57) GAM (5.13)
16 GA (0)  (5.68) GAM (6.58) GAM (UTQ) GAM (UTQ)
17 GAM (0)  (5.41) GAM (5.02) GAM (0) GAM (0)
a The immunoglobulin isotype(s) detected at each time point is designated  (seronegative), G, A, or M. UTQ, unable to quantitate (these samples contained viral
DNA below the linear range of the real-time PCR assay 4,000 copies/ml); NA, not available.
b For patients who developed viruria, urinary viral load in log numbers of copies/ml is indicated.
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immunoglobulin isotypes (r  0.36 to 0.43; P  0.004 to
0.0004) (Fig. 1, lower). Peak plasma viral load showed no
correlation with baseline OD (Fig. 2, upper) but showed direct
correlation with  anti-BK IgM and  anti-BK IgA (Fig. 2,
lower) (r  0.52 and 0.37; P  0.001 and 0.003, respectively).
DISCUSSION
IgG antibodies to BKV VLPs have been measured by sev-
eral groups of investigators (5, 20, 23). All have reported
marked increases in anti-BK IgG antibody titer under condi-
tions associated with viral replication (viruria, viremia, or ne-
phropathy). Elevation of anti-BK IgA and anti-BK IgM class
antibodies in the same clinical setting has been reported in a
retrospective cross-sectional study of kidney transplant pa-
tients at the University of Pittsburgh (42). The current study
examined antibody class and OD in a prospectively collected
set of samples. Serial antibody (IgG, IgA, and IgM) and PCR
measurements provided a direct estimate of the prevalence of
viral replication in primary BKV infection. While the serocon-
version rate was high, only a subset of patients went on to
develop viruria or viremia. Notably, anti-BK IgA antibodies
indicated ongoing viral infection in several patients who were
BKV PCR negative. This is a novel observation that may be
relevant to the control of BKV infection in humans.
In organ transplant recipients, primary infection with
Epstein-Barr virus and cytomegalovirus is considered to be
more severe than reactivation infection (8, 9, 48, 49, 53). Ex-
perience with BKV infection in kidney transplant recipients is
conflicting. Bohl et al. noted a 30.8% rate of viruria in BKV-
seronegative transplant recipients of a seropositive organ (5).
Ginevri et al. initially reported that recipient seronegative sta-
tus, as assessed by a hemagglutination inhibition assay, con-
ferred a significant risk of viral reactivation (58.3%) in relation
to seropositive recipients (21.4%) (21). However, they could
not confirm this in a larger follow-up study using ELISA tech-
nology (20). Hirsch et al. noted that 78.2% of patients shedding
virus-replicating “decoy cells” were seropositive at the time of
transplantation, while 21.8% were seronegative (26, 50). Smith
et al. found that 83.3% of pediatric patients with BKV ne-
phropathy were seronegative for anti-BK IgG antibodies (50).
These discrepancies likely reflect patient selection, small sam-
ple size, geographical differences in viral epidemiology, and
possibly differences in technical methods of assaying anti-BKV
antibodies. It is also possible that the effect of serostatus at the

































































































































































































































































































































































































































































TABLE 6. Diagnostic utility of measuring immunoglobulin isotypes










IgA 0.84 31.6 32.6 66.5 78.5 0.68
IgM 0.24 28.6 95.1 71.7 75.7 0.69
IgG 1.8 41.7 91.2 64.6 76.0 0.71
IgA 0.19 88.0 72.0 57.4 93.3 0.84
IgM 0.04 76.6 76.1 57.9 98.7 0.82
IgG 0.38 85.9 71.7 56.6 92.3 0.87
a Abbreviations: PPV, positive predictive value; NPV, negative predictive value;
ROC/AUC, receiver operating characteristics/area under the curve; IgA, 
anti-BK IgA.
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factors, such as strength of the cell-mediated immune re-
sponse, overall state of immunosuppression, and host or viral
gene polymorphisms.
Seroreversion has not previously been recorded in the
setting of BKV infection. Neither viruria nor viremia was
detectable in seven patients showing this phenomenon, and
it could be argued that seroreversion reflected a loss of
antigenic stimulation. Several patients had viruria present
from a time preceding or concurrent with diagnosis of se-
roreversion. In the latter group of cases, it is possible that
the loss of ability to sustain antibody production reflects loss
of BKV-specific memory B cells (24). The underlying cause
is unclear as there was no augmentation of immunosuppres-
sion in these individuals; indeed, immunosuppression was
reduced in the patients who became viremic. Antiviral treat-
ment has been reported to result in seroreversion in human
FIG. 1. Correlation between immunoglobulin measurements and peak viral load in urine. Baseline OD (upper) showed a weak inverse
correlation for anti-BK IgG, IgM, and IgA, but only the relationship with IgG OD was statistically significant (r  0.25; P  0.05). When  OD
was substituted for baseline OD (lower panel), direct correlations with viral load were found for all three immunoglobulin isotypes (r  0.36, 0.36,
and 0.43 for  anti-BK IgG [Delta IgG],  anti-BK IgA, and  anti-BK IgM, respectively).
FIG. 2. Correlation between immunoglobulin measurements and peak viral load in plasma. Baseline OD (upper) did not show any relationship
with peak plasma viral load. When  OD was substituted for baseline OD (lower panel), a direct correlation was observed with  anti-BK IgM
[Delta IgM] and  anti-BK IgA (r  0.52 and 0.37; P  0.001 and 0.003, respectively). Note that the large majority of samples tested negative for
plasma BKV DNA.
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immunodeficiency virus or hepatitis C virus infection, but
none of our patients received cidofovir, leflunomide, or in-
travenous Ig (2, 29, 32). It is likely that in some patients, the
immunosuppressed state can itself result in a dysregulated
antibody response (3, 25, 33, 38, 46).
With respect to the implications of our findings for clinical
diagnosis, assaying anti-BK IgA and anti-BK IgM antibodies
could certainly provide one means for detecting viral activation
in transplant recipients. Evaluation of at least two samples
would be needed to calculate  OD, since single-point mea-
surements were less reliable in distinguishing PCR-positive
and PCR-negative samples. However, current clinical para-
digms of therapeutic intervention in BKV infection are guided
by the presence of active viral replication, as evidenced by
persistent high-level viruria (	1E07 copies/ml), viremia, or
nephropathy. Quantitative PCR is, therefore, more suited as a
primary screening test for BKV in kidney transplant patients,
even though it cannot detect past exposure, exposure at sites
not related to the body fluid tested, or a recent episode of
reactivation with subsequent viral clearance. On the other
hand, antibody measurements could potentially provide infor-
mation of prognostic value. In our data set, baseline anti-BK
IgG OD showed an inverse correlation with peak urine viral
load. Patients who went on to develop viremia had a lower
baseline seroprevalence of anti-BK IgA. These observations
raise the possibility that preexisting antibody titers play a pro-
tective role and modulate the ultimate clinical outcome of
posttransplant BKV infection. Such a preemptive protective
role is not inconsistent with the opinion of some investigators
that antibodies are not very effective in controlling active viral
replication in patients with active BKV nephropathy (4, 5). It
is likely that anti-VLP antibodies act primarily by binding viral
capsids to prevent intracellular BKV entry and work effica-
ciously only in initial stages of infection. Analogous findings
have been reported by Khoury et al., who studied cytomega-
lovirus infection and observed that donor-seronegative, recip-
ient-seropositive kidney transplant patients show less-severe
viremia than donor-seropositive, recipient-seronegative pa-
tients (30). However, such considerations may not apply to
BKV infection in bone marrow transplant recipients, who typ-
ically undergo intense immunosuppression to maximize the
chance of donor marrow engraftment (7, 52).
In summary, serologic evidence of primary and reactivation
BKV infection is common in kidney transplant patients, but
not all patients develop active viral replication. Primary and
reactivation infections carry similar risks of viruria and viremia,
perhaps pointing to the importance of a donor-derived infec-
tion in both instances. Finally, although larger confirmatory
studies are needed, it appears that immunoglobulin class mea-
surement might provide some prognostic information: in this
series, low anti-BK IgG and IgA titers were associated with
higher peak urinary viral loads and greater risk of viremia.
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